Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials

French National MICMAF Cohort

NCT05895890
Recruiting
Conditions Alcoholic Liver Disease
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Excessive alcohol consumption is a major public health problem, particularly in France. It is the leading cause of cirrhosis and hepatocellular carcinoma. Among subjects with heavy alcohol consumption, the majority of patients develop fatty liver overload (steatosis), but only 10 to 35% develop acute alcoholic hepatitis (AAH) and 8 to 20% progress to cirrhosis. Steatosis is the earliest lesion, rapidly reversible after abstinence from alcohol. On the other hand, the occurrence of AAH leads to a strong progression of fibrosis. The investigators have shown on serial liver biopsies that a subgroup of heavy drinkers develop episodes of AAH and progress to cirrhosis. Therefore, factors other than the amount of alcohol consumed alone influence the development and progression of alcoholic liver disease (ALD). Among these factors, it is now accepted that the gut microbiome plays an important role in the pathogenesis of ALD. Increased intestinal permeability and activation of the innate immune system by lipolysaccharide (LPS) of digestive origin is a key factor in the initiation of AAH. The alteration of the intestinal barrier induced by alcohol abuse seems to involve dysbiosis. Furthermore, the investigatorshave shown that the sensitivity of the liver to alcohol toxicity is transmissible from humans to mice via the gut microbiome. Despite these advances, the causal relationship between mycobiome disruption and ALD in humans requires confirmation in prospective studies. The intestinal microbiome represents all the microorganisms found in the digestive tract: bacteria (bacterial microbiome), viruses (virome), fungi (mycobiome). Recent data point to the role of disturbances of the mycobiome and the virome in human pathology. The intestinal virome consists of two major types of viruses: eukaryotic RNA and DNA viruses that infect host cells and prokaryotic or bacteriophage viruses that infect the bacterial microbiome. Recent evidence suggests that the virome participates in immune system homeostasis. Infection of axenic mice with murine norovirus restores the functionality of intestinal lymphocytes. However, the involvement of the intestinal virome in ALD has never been studied. Cessation of alcohol consumption has a beneficial effect in all stages of ALD . It reduces the risk of complications of cirrhosis and, for early stages of liver damage, prevents progression to advanced stages (severe AAH and cirrhosis). Unfortunately, most patients with alcohol addiction do not achieve long-term abstinence or significant reduction in their consumption despite psychological and medical support. Depression and anxiety are also associated with gut dysbiosis in humans. The causal role, at least partial, of this dysbiosis in addictive phenomena, whether alcohol or other addictions such as cocaine, has been shown. Thus, the modification of MI influences the addictive behavior of cocaine-dependent mice (. All these data show the major role of the microbiota-central…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Genetic: Sequential sampling (stool, saliva, serum) . — Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.

Primary Outcomes

  • Temporal changes in the gut microbiome (every 6 months until 240 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-01
Completion: 2053-02-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigators:
  • Cosmin Voican, Dr (PRINCIPAL_INVESTIGATOR) - Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Cosmin Voican, Dr
01 45 37 47 75
cosmin.voican@aphp.fr
Brahim Mohamed Elarbi
01 40 05 43 60
brahim.mohamed-elarbi@aphp.fr
Cosmin Voican, Dr
0145374775
cosmin.voican@aphp.fr
Cosmin Voican
Interventions
  • Genetic: Sequential sampling (stool, saliva, serum) . — Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
Study Locations (1 sites)
Cosmin Voican, Clamart, Île-de-France Region 92140 France
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 75 years * Average alcohol consumption of more than 20 g per day in women and 30 g per day in men during the previous year; * Patients seen in consultation or hospitalized for assessment of alcoholic liver disease and management of alcohol addiction; * Having given their consent to participate in this study; * Affiliated to a social security system (beneficiary or beneficiary's right). Exclusion Criteria: * Antibiotic, probiotic or prebiotic treatment within the previous 3 months ; * Digestive hemorrhage, acute pancreatitis, acute or chronic diarrhea (except diarrhea related to excessive alcohol consumption) or chronic inflammatory bowel disease; * Another cause of liver damage; * A serious associated pathology (respiratory failure, heart failure, severe psychiatric disorders, active cancer). * Patient under guardianship or curatorship
Conditions Premenstrual Dysphoric Disorder ( PMDD)
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this project is to compare the ovarian hormone levels 7 days after ovulation and progesterone:oestradiol ratios between PMDD individuals and a control cohort (case control study).

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • blood level (5-7 days post ovulation)
  • blood level (5-7 days post ovulation)
  • blood test (5-7 days post ovulation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-05
Completion: 2027-08-01
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lancaster University
Principal Investigators:
  • Chris Gaffney, BSc (Hons.) MSc PhD SFHEA (STUDY_DIRECTOR) - Lancaster University
Contact Information
Study Contact:
Milli Raizada, MBCHB Hons
+44 (0)1524 65201
m.raizada2@lancaster.ac.uk
Milli Raizazda, MBCHB Hons
+44 (0)1524 65201
m.raizada2@lancaster.ac.uk
Lancaster University
Chris Gaffney, BSc (Hons.) MSc PhD SFHEA
+44 (0)1524 65201
c.gaffney@lancaster.ac.uk
Lancaster University
Interventions
N/A
Study Locations (1 sites)
Lancaster University, Lancaster, Lancashire LA1 4YW United Kingdom
Eligibility Criteria
Inclusion criteria * Aged 18-45 years old (adults but less than the typical perimenopausal age so there is not added bias/variable) * Regular menstrual cycles (21-35 days for the last 3 months) * Willing and able to complete a questionnaire (no new clinical diagnosis given) * Use home urine LH test strips to detect ovulation * Attend a single in person on site in Lancaster mid luteal blood test sample appointment (approx 7 days post LH surge) * Provide written informed consent * Have sufficient English language skills to understand the patient information * Be either in Group 1 or group 2 Group 1 (PMDD group ie case group) - self reported prior diagnosis of PMDD made by a healthcare professional (GP, psychiatrist, gynaecologist) Group 2 (Control group ie comparison group) - no prior diagnosis of PMDD made by a healthcare professional and no history of clinically significant premenstrual mood symptoms on screening Exclusion criteria * Current use or use in the last 3 months of hormonal contraception such as the combined oral contraceptive pill, the progestogen only pill, the implant, the injection, hormonal coil (Mirena, Kyleena) or patch/ring. * Current use or use in the last 3 months of any hormone replacement therapy (e.g. combined oestrogen and progesterone, oestrogen and Mirena coil combination, oestrogen alone if had a hysterectomy, or progesterone alone) or GnRH analogues use * On a selective serotonin reuptake inhibitor (SSRI) with a recent initiation or dose change within the last 3 months * Pregnant, breastfeeding or within 3 months post partum * Irregular menstrual cycles (outside the 21-35 day window) * Surgical menopause * Premature ovarian insufficiency * Other endocrine disorders e.g. uncontrolled thyroid disease, high prolactin, cushing's syndrome, polycystic ovarian syndrome) * Regular systemic steroid use or use of other medications known to affect sex hormone within the last 3 months * Severe mental health issues that impair consent or participation * Needle phobic so that venepuncture is intolerable * The use of the emergency contraceptive pill either 3 months prior to the study or during the study.
Conditions Internet-based Intervention, Waiting Lis...
Phase NA
Enrollment 217
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Psychological issues are common among university students and affect mental wellbeing. The Caring Universities (CU) project, involving nine Dutch universities, aims to enhance students' mental health through an annual online questionnaire and a platform offering guided eHealth interventions. One intervention, LifeHack, utilizes cognitive behavioral therapy-based modules to improve mental wellbeing by enhancing resilience and life skills. The effects of LifeHack with pre-post measurements (total n = 216 at post-test) found found that LifeHack led to improvements in mental wellbeing, but dropout rates were influenced by lack of motivation and module relevance. A personalized version of LifeHack is being developed to address these issues and will be evaluated in an RCT to assess its effectiveness in improving mental wellbeing and related outcomes among university students.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: LifeHack — See arm description

Primary Outcomes

  • Mental wellbeing (MHC-SF) (T0 (baseline), T1 (4 weeks post-baseline active group), T2 (4 weeks post-baseline wait list group), T3 (4 weeks post-T2 wait list group), T4 (6 months post-baseline both groups))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-01
Completion: 2025-07-31
Eligibility
Age: 16 Years – 99 Years
Sex: ALL
Volunteers: true
Enrollment: 217 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universiteit Leiden
Collaborators: Maastricht University, VU University of Amsterdam, Utrecht University, University of Amsterdam, Rotterdam University of Applied Sciences, Erasmus University Rotterdam, Avans University of applied sciences, InHolland University of Applied Sciences
Principal Investigators:
  • Sanne van Luenen, PhD (PRINCIPAL_INVESTIGATOR) - Leiden University
Contact Information
Study Contact:
Sanne van Luenen, PhD
0031-715277957
s.van.luenen@fsw.leidenuniv.nl
Sanne van Luenen
VU Amsterdam
Sanne van Luenen
Leiden University
Interventions
  • Behavioral: LifeHack — See arm description
Study Locations (2 sites)
VU Amsterdam, Amsterdam, Netherlands
Leiden University, Leiden, Netherlands
Eligibility Criteria
Inclusion Criteria: * Being fluent in Dutch and/or English * Being enrolled as a student at one of the 9 participating universities * Being 16 years of age or older * Having access to a PC or mobile device with internet access * Provide informed consent before participation * Score of 50 or lower on the MHC-SF. This is 1 SD above the mean baseline score of participants of LifeHack. This inclusion criterion ensures no students with optimal mental wellbeing are included because they will not be able to show any change.
Conditions Major Depressive Disorder
Phase NA
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a study that will recruit patients from the neurosurgery clinic and the regular TMS clinic. It's a smaller study designed to collect brain imaging pre-treatment and then use image guided TMS to treat patient with a one week "accelerated" rTMS protocol using the research TMS machine that is housed in Dr. Sean Nestor's lab. The idea is to examine whether severe treatment resistant depression has a different brain signature than less severe/TRD and whether the investigators can get a therapeutic response from patients that would otherwise undergo neurosurgery or will ultimately undergo neurosurgery.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: rTMS — Accelerated iTBS treatment

Primary Outcomes

  • Change in depressive symptomatology (3 years)
  • Imaging (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-27
Completion: 2025-07-07
Eligibility
Age: 20 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Contact Information
Study Contact:
Anusha Baskaran, PhD
416-480-6100
anusha.baskaran@sunnybrook.ca
aNUSHA Basakran, PhD
416-480-6100
anusha.baskaran@sunnybrook.ca
Sunnybrook Health Sciences Centre
Interventions
  • Device: rTMS — Accelerated iTBS treatment
Study Locations (1 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N3M5 Canada
Eligibility Criteria
Inclusion criteria: * Age 20-65 * Have a diagnosis of MDD or persistent depressive disorder and meet criteria for a major depressive episode (moderate-severe) according to the DSM 5.0 with a 17-item Hamilton Rating Scale Score in Depression (HRSD-17) of \>=18 * UTRD subjects will also have a duration of depressive symptoms \>=5 years, treatment resistance to antidepressants will be defined by Maudsley-staging, failing \>6 antidepressants (level 4) and \>1 adjunctive antidepressants of adequate dose/duration, failed at \>=1 psychotherapy, and no response to \>=1 trial of esketamine, IV ketamine, ECT or rTMS * Milder TRD participants will have failed at least 1 antidepressant medication of adequate dose/duration and never had neuromodulation treatment Exclusion criteria: * Contraindications to MRI * Medical/psychiatric co-morbidities that prevent participation in the study or where depression is not the primary psychiatric symptom of concern * History of psychosis, pregnancy, substance dependence within the last 6 months * Active neurological disorder * History of seizure disorder * Cognitive impairment * Unable to provide informed consent on their own * Pregnant
Conditions Major Depressive Disorder (MDD), Treatme...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to collect feasibility data on combining structured exercise aimed to improve physical fitness, and intermittent TBS (iTBS) in treating individuals diagnosed with difficult-to-treat depression who are physically inactive. By conducting this trial, we will compare the therapeutic benefits of the combined approach against the standard treatment of iTBS alone (without exercise). These findings will be used to inform future large-scale projects in which we will investigate, in a larger sample size, whether structured exercise aimed to improve fitness as recommended by most public exercise guidelines (i.e., ≥3x/week, moderate-to-vigorous intensity) serves as an active ingredient that amplifies the effectiveness of iTBS. Ultimately, the insights gained from this study will be valuable for clinicians seeking to alleviate depressive symptoms in MDD through neuromodulation techniques such as iTBS.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Theta burst stimulation — Cool B70 cooled-coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Primary Outcomes

  • Assessing feasibility on combining structured exercise and intermittent Theta Burst Stimulation (iTBS) in participants with treatment-resistant depression (TRD) (Assessed at the end of the study once all participants have completed the study.)
  • Compare the effects on clinical response of exercise on enhancing iTBS treatment efficacy vs. iTBS alone (Administered at screening, before iTBS treatment course (week 4), at the end of the treatment course (week 10), then at the 6-week follow-up (week 16))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2027-01-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Royal Ottawa Mental Health Centre
Collaborators: University of Ottawa
Principal Investigators:
  • Sara Tremblay, PhD (PRINCIPAL_INVESTIGATOR) - Royal Ottawa Mental Health Centre
Contact Information
Study Contact:
Stacey Shim, MSc
613-722-6521
stacey.shim@theroyal.ca
Emma Cummings, BSc
6137226521
emma.cummings@theroyal.ca
Stacey Shim
6137226521
stacey.shim@theroyal.ca
Royal Ottawa Mental Health Centre
Interventions
  • Device: Theta burst stimulation — Cool B70 cooled-coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
Study Locations (1 sites)
Royal Ottawa Mental Health Centre, Ottawa, Ontario k1z 7k4 Canada
Eligibility Criteria
Inclusion Criteria: 1. Are between 18-75 years old. 2. Able to provide voluntary informed consent. 3. Diagnosis of MDD or Persistent Depressive Disorder, without psychotic features, confirmed by MINI for DSM-5. 4. Depressive symptoms have not improved after ≥ 1 adequate antidepressant trial in the current episode (i.e., difficult-to-treat MDD), based on the Antidepressant Treatment History Form (ATHF). 5. Baseline score of ≥15 on the HRSD-17. 6. No change in psychotropic medications or psychotherapy regimen at least 4 weeks prior to entering the trial 7. Physically inactive as per the International Physical Activity Questionnaire - Short Form (IPAQ-SF). 8. Able to engage in structured exercise as per the Get Active Questionnaire (GAQ). 9. Able to adhere to the proposed treatment schedule. Exclusion Criteria: 1. Diagnosis of bipolar I or II disorder, based on DSM-5 criteria. 2. Current or past (\<3 months) substance (excluding caffeine or nicotine) or alcohol abuse/dependence, as defined in DSM-5 criteria. 3. Current use of illegal substances. 4. Current use of cannabis. 5. Concomitant major unstable medical or neurologic illness (e.g., uncontrolled diabetes or renal dysfunction). 6. Organic cause of the depressive symptoms (e.g. thyroid dysfunctions), determined by the referring physician. 7. Acute suicidality or threat to life from self-neglect. 8. Pregnant or breastfeeding, or thinking of becoming pregnant during course of treatment. 9. Contraindication for TMS and MRI (e.g., personal history of epilepsy or seizure, metallic head implant, pacemaker), confirmed by TMS Adult Safety Scale (TASS) and MRI pre-screener. 10. Unwilling to maintain current psychotropic medication and/or psychotherapy regimen for the four weeks prior to and for the duration of the study. 11. Taking more than 1 mg/day of lorazepam or equivalent. 12. Any other condition that, in the opinion of the investigators which would adversely affect the participant's ability to complete the study. 13. Physically active: performing exercise and/or physical activity levels meeting the cut-off for "minimally active" on the IPAQ-SF.
Conditions Substance Abuse, Intimate Partner Violen...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to prevent syndemic health conditions by decreasing acculturative stress and promoting resilience via SER Familia (Salud, Estrés y Resilencia en Familias/ Health, Stress, and Resilience in Families), a family-based intervention. SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH). More specifically, investigators aim to: 1) Examine the efficacy of SER Familia to prevent or reduce the syndemic comprised of substance abuse, IPV, HIV risk, depression, and anxiety among Parents and Youth; and 2) Identify how individual, family, and community mechanisms of change related to acculturative stress and resilience mediates the effect of SER Familia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: SER Familia — SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).

Primary Outcomes

  • Change in Parent Acculturative stress as measured by the Hispanic Stress Inventory (HSI-2) Immigrant Version (From Enrollment to end of treatment at 6 weeks)
  • Change in Youth Acculturative stress as measured by the Hispanic Stress Inventory - Adolescent (HSI-A) (From Enrollment to end of treatment at 6 weeks)
  • Change in individual resilience as measured by the 25-item Resiliency Scale (From Enrollment to end of treatment at 6 weeks)
  • Change in PROMIS (Patient-Reported Outcomes Measurement Information System) Global Health (From Enrollment to end of treatment at 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-30
Completion: 2029-01-31
Eligibility
Age: 12 Years – 100 Years
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Contact Information
Study Contact:
Rosa Gonzalez-Guarda, PhD
9196132634
rosa.gonzalez-guarda@duke.edu
Norma Garcia-Ortiz, BS
9196849331
norma.garcia.ortiz@duke.edu
Rosa Gonzalez-Guarda, PhD
919-684-9331
rosa.gonzalez.guarda@duke.edu
Duke School of Nursing
Interventions
  • Behavioral: SER Familia — SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).
Study Locations (1 sites)
Duke School of Nursing, Durham, North Carolina 27707 United States
Eligibility Criteria
Inclusion Criteria: * Eligible participants must identify as Hispanic/Latino/a/x/e, * be a first generation immigrant parent or parental figure (Parent) * have a child (Youth) aged 12-17 * speak English and/or Spanish Exclusion Criteria: * Families planning to move within two years will be excluded
Conditions Stress
Phase NA
Enrollment 156
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial will investigate whether a powdered prebiotic fibre blend can improve perceived stress levels in healthy adults with mild-severe stress levels.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Prebiotic fibre blend — A blend of prebiotic fibres in a powdered supplement form.
  • Dietary Supplement: Maltodextrin powder — Maltodextrin powder

Primary Outcomes

  • Perceived Stress (Baseline and 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-02
Completion: 2026-12-30
Eligibility
Age: 18 Years – 50 Years
Sex: ALL
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Myota GmbH
Collaborators: University of Reading
Contact Information
Study Contact:
Caitlin Hall, PhD, RD
07830709854
caitlin@myotahealth.com
Caitlin Hall, PhD
07830709854
caitlin@myotahealth.com
CALM Study Site
Interventions
  • Dietary Supplement: Prebiotic fibre blend — A blend of prebiotic fibres in a powdered supplement form.
  • Dietary Supplement: Maltodextrin powder — Maltodextrin powder
Study Locations (1 sites)
CALM Study Site, London, EC2A 4BQ United Kingdom
Eligibility Criteria
Inclusion Criteria: * Aged 18-50 years of age * Capacity to give informed consent to participate in the study * Able to comply with study requirements and visits * Meet the range required for mild-severe stress levels (as assessed by DASS-42 stress subscale) * Normal or corrected to normal vision and/or hearing Exclusion Criteria: * Current smoker * Having food allergies and/or intolerances * Diagnosis of Type 1 or 2 diabetes or cardiovascular disease or psychiatric or neurological conditions (e.g. schizophrenia, dementia) including eating disorders * Current or previous diagnosis of depression in past 6 months * Receiving medications that lower cholesterol, blood pressure, blood glucose levels, or improve insulin sensitivity * Receiving antidepressant or anti-anxiety medications or treatments * Receiving hormonal birth control * Perimenopause or menopause * Pregnancy, lactation, or an intent to become pregnant during the course of the study * Continuous antibiotic use for \> 3 days within 1 month prior to enrolment * Continuous use of weight-loss drug for \> 1 month before screening * Major change in dietary intake in past month (e.g. excluding whole food groups) * Currently consuming daily prebiotic or probiotic supplements * Prior use (\< 6 months) of any blood glucose or cholesterol lowering medication * Any significant GI condition affecting GI absorption including (but not limited to) inflammatory bowel disease, weight loss surgery, irritable bowel disease. * End stage renal disease * Active cancer, or treatment for any cancer, in last 3 years * Consuming more than 20g of fibre a day as assessed by the 18-item FiberScreen
Conditions Psychiatric Disorder, Depression, Anxiet...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Many psychiatric patients are not sufficiently improved by current interventions. Functional magnetic imaging brain imaging (fMRI) has proven to be a promising method for predicting treatment outcomes in psychiatric treatment. Individuals moment-to-moment variability have not yet been evaluated as a predictor of treatment of three common forms of mental illness: depression, insomnia and health anxiety. The goal is to investigate whether objective measurements of brain function contribute to a better prediction of a patient's success in treatment than experiences and self-reports, e.g., treatment credibility and patients expectations about the treatment. The prediction model will be tested on internet-delivered CBT (iCBT) for depression, insomnia and social anxiety. Patients in each diagnostic group are asked for participation before treatment. The total number of participants in this study will amount to 225 participants. The goal is that 35% consists of healthy controls and that the remaining part is equally distributed between the three diagnostic patient groups. Being able to better predict how well a psychiatric treatment will work for an individual has great value from both an economic and a treatment perspective. The findings from this study may contribute to increased knowledge about neurobiological complications in mental illness. In the longer term, it can lead to improved routines and help in clinical decision-making when patients should be recommended treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Internet-delivered cognitive behavioral therapy for major depressive disorder — Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
  • Behavioral: Internet-delivered cognitive behavioral therapy for insomnia — Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
  • Behavioral: Internet-delivered cognitive behavioral therapy for social anxiety disorder — Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.

Primary Outcomes

  • Change from Baseline Patient Health Questionnaire 9 - Self Assessment (PHQ-9) to Post-treatment (Up to 6 months)
  • Change from Baseline Insomnia Severity Index - Self Assessment (ISI) to Post-treatment (Up to 6 months)
  • Change from Baseline Liebowitz Social Anxiety Scale - Self Assessment (LSAS-SR) to Post-treatment (Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-04-01
Completion: 2026-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Principal Investigators:
  • Kristoffer Kristoffer, PhD (PRINCIPAL_INVESTIGATOR) - Department of Clinical Neuroscience, Karolinska Institutet
Contact Information
Study Contact:
Kristoffer Kristoffer, PhD
+46(0)705803267
kristoffer.mansson@ki.se
Viktor Kaldo, PhD
viktor.kaldo@ki.se
Erik Forsell, PhD
+46704903681
erik.forsell@ki.se
Internetpsykiatri
Interventions
  • Behavioral: Internet-delivered cognitive behavioral therapy for major depressive disorder — Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
  • Behavioral: Internet-delivered cognitive behavioral therapy for insomnia — Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
  • Behavioral: Internet-delivered cognitive behavioral therapy for social anxiety disorder — Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
Study Locations (1 sites)
Internetpsykiatri, Huddinge, Stockholm County 14152 Sweden
Eligibility Criteria
Inclusion Criteria: * Meeting DSM-5 criteria for depression, social anxiety or insomnia. Diagnosis and measures of symptom burden and functional level are made through a structured interview, the Mini-International Neuropsychiatric Interview (M.I.N.I.) and self-assessments of symptoms. Healthy controls should not be relevant to psychiatric treatment nor meet criteria for any psychiatric condition according to the M.I.N.I. * Being able to read, write and speak Swedish in order to be able to read the treatment texts and be able to make phone calls. * Having basic computer skills to be able to complete surveys via the Internet and access the treatment platform. Exclusion Criteria: * Physical or mental illnesses who are either contraindicated for treatment (for example, bipolar disorder that can be exacerbated by treatment) or for other reasons need other treatments (e.g. severe depression, suicidal behavior, psychotic illnesses or extensive cognitive difficulties). * High alcohol consumption or other ongoing drug use. * Answering "yes" to any of the following questions will be excluded for participation: 1) "Have you or have you had any electrical / battery operated implants in your body? For example, a pacemaker, medication pump, neurostimulator, hearing implant, or other electrical / battery controlled implant?" 2) "Have you done any surgery on the abdomen, chest, heart or brain, eyes, ears? For example, vessel clips, or objects such as screws, heart valve, shunt or prosthesis?" 3) "Do you have or have you had any metallic object in your body?" 4) "If a woman, are you pregnant or breastfeeding?" 5) "Do you undergo dialysis or have kidney dysfunction?" Participants who answer yes to these follow-up questions will be interviewed more closely to determine if MRI security can be guaranteed and whether the MRI signal will have significant disruptions, for example due to dental scaffolding. 1) "If you have any abdominal, thoracic, heart or brain, eyes, ears? Do you have any inoperable object that has ferromagnetic properties?" The patient will be asked to consult his doctor about this. 2) "If you have a dental rack, what type of dental rack (fixed or removable, metal plates / rails or wire)"?
Conditions Treatment Resistant Depression (TRD), Ma...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in cases where patients have not responded well to traditional therapies. Treatment will be delivered over a 2-week period with daily weekday treatments i.e., five tDCS sessions, each lasting 20 minutes, spaced by approximately 20-minute inter-session intervals, for a total of three hours a day. Participants will self-administer treatment at home under direct remote supervision. Pre- and post- treatment neurophysiological biomarkers sessions will also be carried out. The study aims to examine changes in mood, brain activity, and related clinical outcomes before, during, and after treatment, with the goal to provide more information that can be used for future studies. PLEASE NOTE: THERE WILL BE 4 APPOINTMENTS THAT MUST OCCUR IN PERSON IN SAN DIEGO, CA.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Spaced Transcranial Direct Current Stimulation (tDCS) — tDCS will be self-administered at home under the supervision of a trained clinical research coordinator using the Soterix Medical mini-CT device with remote monitoring via a secure videoconferencing platform (e.g., Microsoft Teams).The device is designed for safe, remote tDCS delivery. Participants will be treated using a stimulation at 2 mA, with a 30-second ramp-up and ramp-down phase.

Primary Outcomes

  • Feasibility (Recruitment) (From baseline clinical assessment prior to treatment to 12 weeks after last treatment.)
  • Feasibility (Retention) (From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.)
  • Feasibility (Adherence) (From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.)
  • Safety of at-home spaced tDCS (From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.)
  • Tolerability to spaced tDCS (From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-27
Completion: 2027-03-01
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Contact Information
Study Contact:
Interventional Psychiatry
858-966-5832
iptrials@health.ucsd.edu
Edith Jimenez
858-657-6149
iptrials@health.ucsd.edu
UCSD Interventional Psychiatry
UCSD Interventional Psychiatry Clinic
(858)207-0938
iptrials@health.ucsd.edu
UCSD Interventional Psychiatry
Interventions
  • Device: Spaced Transcranial Direct Current Stimulation (tDCS) — tDCS will be self-administered at home under the supervision of a trained clinical research coordinator using the Soterix Medical mini-CT device with remote monitoring via a secure videoconferencing platform (e.g., Microsoft Teams).The device is designed for safe, remote tDCS delivery. Participants will be treated using a stimulation at 2 mA, with a 30-second ramp-up and ramp-down phase.
Study Locations (1 sites)
UCSD Interventional Psychiatry, San Diego, California 92127 United States
Eligibility Criteria
Inclusion Criteria: 1. People between the ages of 18 and 85 at the time of screening. 2. Currently diagnosed with Major Depressive Disorder (MDD) as measured by the MINI and a MADRS score of ≥ 20. 3. Safe for TMS as measures by the TMS Adult Safety Screening (TASS). 4. Medical records confirming a history of failing to achieve clinical response to an adequate antidepressant trial as defined an Antidepressant Treatment History Form (ATHF) score ≥ 3 or ) or shown intolerance to at least two inadequate trials (score 1 or 2), without psychiatric illness due to a general medical condition. 5. Stable internet connection and a device compatible with Microsoft Teams. Exclusion Criteria: 1. History of psychotic or bipolar disorder or depression with psychotic features; 2. Significant borderline personality disorder; 3. Significant comorbid obsessive-compulsive or post-traumatic stress: 4. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal; 5. Clinically significant suicidality disorder; 6. Chronic depression (defined as of over 5 years duration); 7. Pregnancy or lactation, lack of adequate birth control in women of childbearing age; 8. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent symptoms; 9. Unstable medical illness; 10. Contraindication to receiving tDCS (e.g., ferromagnetic implant, history of seizure, known brain lesion); 11. History of TMS (greater than 15 sessions) without a clinically meaningful response.; History of ketamine (greater than 4 sessions) without a clinically meaningful response; 12. Require a benzodiazepine with a dose \> lorazepam 2 mg/day; 13. dermatological conditions contraindicating tDCS; 14. Non-correctable sensory impairments; 15. Inability to consent or participate as an outpatient
Conditions Depressive Disorder, Major, Inflammation
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Infliximab — Intravenous infusion of infliximab
  • Other: Placebo — Intravenous infusion of saline solution (matching in color and consistency in infliximab)

Primary Outcomes

  • Psychomotor Speed (TestMyBrain: Simple Reaction Time) (Repeated measures over two weeks)
  • Executive Function (TestMyBrain: Choice Reaction Time) (Repeated measures over two weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-23
Completion: 2029-01-31
Eligibility
Age: 25 Years – 50 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Contact Information
Study Contact:
Naoise Mac Giollabhui, PhD
6177241000
nmacgiollabhui@mgh.harvard.edu
Naoise Mac Giollabhui, PhD
6177241000
nmacgiollabhui@mgh.harvard.edu
Massachusetts General Hospital
Naoise Mac Giollabhui, PhD
Massachusetts General Hospital
Interventions
  • Drug: Infliximab — Intravenous infusion of infliximab
  • Other: Placebo — Intravenous infusion of saline solution (matching in color and consistency in infliximab)
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Aged 25-50 years 2. Able to read and understand English and willing to provide informed consent/comply with the study protocol 3. Willingness to complete intravenous infusion and have blood drawn 4. Exhibit circulating blood level of C reactive protein ≥ 3mg/L 5. Diagnosed with Major Depressive Disorder 6. Moderate depressive symptom severity, as indicated by score ≥15 on the Hamilton Depression Rating Scale 7. Antidepressant treatment free for at least 4 weeks prior to study entry or be on a fixed treatment regimen for at least 4 weeks; willingness to continue treatment status (i.e., change/begin new treatment) until study termination 8. Willingness not to begin/change therapies until study termination (maximum of three weeks following screening) 9. Be of non-childbearing potential per the following specific criteria: a. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is post-menopausal with her last menses at least one year prior to screening); or b. Childbearing potential and meets the following criteria: i. A negative serum pregnancy test within thirty days of infusion (may be repeated closer to infusion date at the discretion of the PI or study staff) and abstinent after the negative serum pregnancy test and prior to infusion; or ii. Using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent; iii. Continuously use one of the following methods of birth control over the last six months: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. Exclusion Criteria: 1. Medical conditions that could confound interpretation or increase participant risk, as indicated via medical history or laboratory testing; exclusionary medical conditions will include: i. acute injury/infection within one week of study initiation or infection within one month of study initiation that required antibiotic/antiviral treatment ii. chronic infection (e.g., hepatitis B or C or HIV) or history of Covid 19 infection within the past 6 months or with persisting symptoms. iii. latent infection (e.g., tuberculosis, fungal infections), or history of recurrent infections, iv. uncontrolled cardiovascular, endocrine, hematologic, hepatic, renal or neurologic disease (as determined by medical history, physical exam and laboratory testing) v. cancer history vi. autoimmune conditions; neurologic conditions (controlled) that are known to substantially impact cognitive function (e.g., stroke). Of note, stable medical conditions such as diabetes and cardiovascular disease, will be allowed in the study as they can contribute to endogenous inflammation. 2. Active antipsychotic and anticonvulsant medication use (that interact with infliximab) 3. Prior use of a TNF antagonist or use of systemic corticosteroids or anti-proliferative agents within one year of study entry 4. History of liver abnormalities 5. Major cognitive impairment as determined by study investigators 6. Active restrictive eating disorder or obsessive compulsive disorder deemed by study investigators to be primary cause of depressive disorder 7. History of a psychotic disorder or Bipolar disorder type I/II 8. Current substance use disorder (i.e., present in last six months), of greater than mild severity 9. Suicidal ideation based on a score ≥3 on the Columbia-Suicide Severity Rating Scale 10. Electroconvulsive therapy (ECT)/deep brain stimulation (DBS) within the last year, or report of persistent negative cognitive effects of ECT/DBS 11. Presence of a transplanted solid organ 12. Medication use affecting immune or cognitive function: i. Chronic use (\>1 month) of a benzodiazepine more than the equivalent of 2 mg of lorazepam ii. Use of anti-inflammatory agents during the study: non-steroidal anti-inflammatory agents (NSAIDs) (excluding 81mg of aspirin), glucocorticoid containing medicines or statins, or cyclooxygenase-2 (COX-2) inhibitors 13. Considered by the study investigators to be inappropriate for the study due to safety concerns or to be unlikely to complete the protocol 14. History of allergic response to murine products
Conditions Moral Injury
Phase NA
Enrollment 3073
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Healthcare professionals are facing an escalating crisis, with burnout rates ranging between 40% and 60% and a growing intention to leave the profession, affecting one in five physicians and one in four nurses in the coming years. While current interventions focused on individual resilience, such as mindfulness, peer support, and workload management, have been promoted as solutions, they have failed to bring about systemic improvements. This raises the question of whether other factors, such as Moral Injury, play a key role in this crisis. Moral Injury is an emerging concept that highlights the profound misalignment between healthcare workers' professional values and the reality of their practice, often exacerbated by organizational and economic constraints. The objective of this study is to describe the manifestations of Moral Injury among healthcare professionals in France. By establishing the first large-scale assessment of Moral Injury among healthcare professionals in France, this study aims to identify key organizational and personal risk factors contributing to this phenomenon. The use of Structural Equation Modeling will help build a robust theoretical model that clarifies the underlying mechanisms of Moral Injury and its interactions with broader health issues. The findings will support the development of targeted interventions focused on systemic organizational changes to improve healthcare workers' well-being and guide public health policies.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Self-Questionnaires for Healthcare Workers — Health workers will be invited to complete an online self-questionnaire.

Primary Outcomes

  • Moral Injury Inventory for Healthcare Professionals (One point : baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-19
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 3073 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Principal Investigators:
  • Laurent BOYER, Pr (STUDY_DIRECTOR) - CEReSS
Contact Information
Study Contact:
Sophie LAFOND
0483772062
sophie.lafond@ch-toulon.fr
Sophie LAFOND
0483772062
sophie.lafond@ch-toulon.fr
Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer
Laurent BOYER, Pr
Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer
Interventions
  • Other: Self-Questionnaires for Healthcare Workers — Health workers will be invited to complete an online self-questionnaire.
Study Locations (1 sites)
Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer, Toulon, Var 83100 France
Eligibility Criteria
Inclusion Criteria: * Healthcare workers Exclusion Criteria: * Absence of consent
Conditions Major Depressive Disorder
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to primarily assess the feasibility and secondarily assess the efficacy of a single session intervention (SSI) that combines non-invasive brain stimulation and psychotherapy for Major Depressive Disorder (MDD). investigators will recruit 30 people with MDD, with at least mild to moderate symptoms, who are resistant to typical treatments for Major Depressive Disorder. In this trial, participants will receive psychotherapy, Intermittent Theta Burst Stimulation Transcranial Magnetic Stimulation (iTBS), and either active or sham (placebo) Transcranial Alternating Current Stimulation (tACS).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Intermittent Theta Burst Stimulation (iTBS) — The TMS stimulation will be delivered using the MagPro X100 system (MagVenture Inc., Alpharetta, Georgia, USA). Participants will receive theta-burst stimulation (iTBS) consisting of 1,800 biphasic pulses delivered in bursts of three pulses at 50 Hz, repeated at 5 Hz (2-s trains, 8-s inter-train interval, 30 trains total per block), at an intensity of 90 % of the resting motor threshold. TMS will be delivered before each tACS/therapy block (over the tACS electrodes), totaling 5 blocks of TMS throughout the single session intervention.
  • Device: Transcranial Alternating Current Stimulation (tACS) — The alpha and -theta tACS stimulation will be delivered using the neuroConn DC Stimulator MC.The interventional tACS stimulation will be 120 minutes of tACS total; 60 minutes will be delivered during the second block of therapy and 60 minutes will be delivered during the third block of therapy.F3 and F4 will be stimulated 'in-phase', with 1 mA applied at each location, and Cz will be stimulated 'anti-phase' with 2mA applied (zero to peak). tACS will be delivered with a 20 second ramp up and ramp down, at the beginning and end of stimulation. The stimulation amplitude delivered is standard for tACS studies conducted in the Frohlich Lab.
  • Behavioral: Psychotherapy — The three, 1-hour psychotherapy blocks were designed to incorporate effective components from multiple psychotherapies, with an emphasis on functional analysis to define the presenting concern, followed by Behavioral Activation (BA) and Acceptance and Commitment Therapy modules to target low mood and psychological flexibility, respectively. The SSI was designed to incorporate ACT principles throughout the modules, guided by the tenets of psychological flexibility, as described by Hayes. Be present, open up, do what matters. The manual was created by a team of several advanced clinical trainees and two licensed clinical psychologists. The last 10 minutes of each session will be spent briefly reviewing the day's activities, what stood out for participants (negative or positive), and whether they had feedback for the clinician.
  • Device: Sham (Placebo) Transcranial Alternating Current Stimulation (tACS) — Participants will be fitted with the same tACS setup and will receive sham tACS in which alpha-theta tACS is delivered for 40 seconds before ramping down to close to 0 mA of current (20 second ramp up and ramp down; total 80 seconds of stimulation). This active sham is designed to mimic the sensation of receiving stimulation without delivering a sufficient dose of tACS to influence the efficacy of the SSI.

Primary Outcomes

  • Safety via the presence of any serious AEs (Day 0 (Baseline) to Day 90 (Follow-up 2))
  • Feasibility of the Single Session Intervention (Day 0 (Baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-14
Completion: 2028-07-01
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: Foundation of Hope, North Carolina
Principal Investigators:
  • Flavio Frohlich, PhD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Flavio Frohlich, PhD
919-966-9929
flavio_frohlich@med.unc.edu
Haileigh Taylor, BA
919-966-9929
hjtay@unc.edu
Flavio Frohlich, PhD
919-966-9929
flavio_frohlich@med.unc.edu
Carolina Center for Neurostimulation
Interventions
  • Device: Intermittent Theta Burst Stimulation (iTBS) — The TMS stimulation will be delivered using the MagPro X100 system (MagVenture Inc., Alpharetta, Georgia, USA). Participants will receive theta-burst stimulation (iTBS) consisting of 1,800 biphasic pulses delivered in bursts of three pulses at 50 Hz, repeated at 5 Hz (2-s trains, 8-s inter-train interval, 30 trains total per block), at an intensity of 90 % of the resting motor threshold. TMS will be delivered before each tACS/therapy block (over the tACS electrodes), totaling 5 blocks of TMS throughout the single session intervention.
  • Device: Transcranial Alternating Current Stimulation (tACS) — The alpha and -theta tACS stimulation will be delivered using the neuroConn DC Stimulator MC.The interventional tACS stimulation will be 120 minutes of tACS total; 60 minutes will be delivered during the second block of therapy and 60 minutes will be delivered during the third block of therapy.F3 and F4 will be stimulated 'in-phase', with 1 mA applied at each location, and Cz will be stimulated 'anti-phase' with 2mA applied (zero to peak). tACS will be delivered with a 20 second ramp up and ramp down, at the beginning and end of stimulation. The stimulation amplitude delivered is standard for tACS studies conducted in the Frohlich Lab.
  • Behavioral: Psychotherapy — The three, 1-hour psychotherapy blocks were designed to incorporate effective components from multiple psychotherapies, with an emphasis on functional analysis to define the presenting concern, followed by Behavioral Activation (BA) and Acceptance and Commitment Therapy modules to target low mood and psychological flexibility, respectively. The SSI was designed to incorporate ACT principles throughout the modules, guided by the tenets of psychological flexibility, as described by Hayes. Be present, open up, do what matters. The manual was created by a team of several advanced clinical trainees and two licensed clinical psychologists. The last 10 minutes of each session will be spent briefly reviewing the day's activities, what stood out for participants (negative or positive), and whether they had feedback for the clinician.
  • Device: Sham (Placebo) Transcranial Alternating Current Stimulation (tACS) — Participants will be fitted with the same tACS setup and will receive sham tACS in which alpha-theta tACS is delivered for 40 seconds before ramping down to close to 0 mA of current (20 second ramp up and ramp down; total 80 seconds of stimulation). This active sham is designed to mimic the sensation of receiving stimulation without delivering a sufficient dose of tACS to influence the efficacy of the SSI.
Study Locations (1 sites)
Carolina Center for Neurostimulation, Chapel Hill, North Carolina 27516 United States
Eligibility Criteria
Inclusion Criteria: * Any gender, aged 18 - 70 * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * DSM-5 diagnosis of unipolar, non-psychotic MDD as evidenced by the Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive and Related Neuropsychiatric Disorders (DIAMOND) * HDRS-17 score ≥14 * Low suicide risk (defined for this study as no active suicidal ideation in the past month and no suicide attempts, preparatory actions, or significant non-suicidal self-harm in the previous 2 years). Risk will be assessed utilizing the Columbia-Suicide Severity Rating Scale (C-SSRS) screen and triage version with further exploration of positive responses. * Capacity to understand all relevant risks and potential benefits of the study (informed consent). * For people of childbearing potential: use of highly effective contraception as determined by the Investigator for at least 1 month prior to screening and agreement to use such a method during study participation * History of treatment resistance as indicated by previously or currently not achieving clinically significant symptom reduction on at least one antidepressant medication. This will be evaluated using the Maudsley Treatment Inventory (MTI). Participants with scores greater than or equal to 3 on the MTI will be included. Exclusion Criteria: * DSM-5 diagnosis of severe alcohol use disorder (AUD) within the last 12 months, as evidenced by the DIAMOND * DSM-5 diagnosis of moderate to severe substance use disorder (excluding tobacco) within the last 12 months, as evidenced by the DIAMOND * Lifetime history of bipolar disorder, as evidenced by DIAMOND * Schizophrenia spectrum and other psychotic disorders, as evidenced by DIAMOND * History of autism spectrum disorder (self-reported by participants) * Initiated any new psychotropic medication in the 6 weeks prior to screening or had a dose change in the preceding 6 weeks * Initiated a new course of psychotherapy in the 6 weeks preceding screening * Received any neurostimulation treatment in the 6 weeks preceding screening * History of seizures (excluding febrile seizures in childhood or Electroconvulsive Therapy (ECT) induced seizures) * Neurological disorders that would increase risk of participation or present a significant confounder in the opinion of the investigator (for example, dementia, history of stroke, Parkinson's disease, multiple sclerosis, history of traumatic brain injury with prolonged loss of consciousness, ruptured cerebral aneurysm, previous CNS radiation) * Previously failed to respond to ECT or transcranial magnetic stimulation (TMS) * Prior brain surgery and/or brain implants * Personal or familia history of epilepsy * Previous fainting spells or syncope * Metal in the brain, skull or elsewhere in the body * Implanted medical device that uses electricity and any implanted devices in other areas of the head or neck, or implants located \< 30cm from the position of the TMS coil * Current pregnancy or lactation * Currently enrolled in another clinical trial for depression * Unstable medical disorder or anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the opinion of the Investigator * Non-English speaking individuals are excluded because the ability to accurately and completely communicate study information, answer questions about the study, and obtain consent in the English language are necessary, and due to resource constraints it is not feasible to engage an interpreter for language services.